Enhua Pharmaceutical said on an interactive platform on October 28 that the company's Forli and Liyuexi injections currently have no sleeping indications and have not been applied to short-term intravenous sedation to treat insomnia. Currently, the development of sleep clinics in China has had no impact on the revenue of these two products for the time being. The company is also actively following clinical research on short-term intravenous sedation in some domestic hospitals using Liyuexi and Fulley to treat insomnia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.